β-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease

Molecular and Cellular Biochemistry

Volumn 418, Issue 1-2, 2016, Pages 59-70

  Ojha, Shreesh ^a   Javed, Hayate ^a   Azimullah, Sheikh ^a   Haque, M Emdadul ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Neurodegeneration; Neurotoxicity; Parkinson disease; Rotenone; Caryophyllene

Indexed keywords

ADAPTOR PROTEIN; CARYOPHYLLENE; CATALASE; CYCLOOXYGENASE 2; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; IONIZED CALCIUM BINDING ADAPTOR MOLECULE 1; LIPID; MALONALDEHYDE; ROTENONE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CANNABINOID; SESQUITERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; BRAIN LEVEL; CELL ACTIVATION; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; CYTOKINE PRODUCTION; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; GLIA CELL; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIPID PEROXIDATION; MALE; MESENCEPHALON; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN DEPLETION; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA PARS COMPACTA; TREATMENT OUTCOME; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; GLIA; METABOLISM; PARKINSON DISEASE, SECONDARY; PATHOLOGY;

ANIMALS; CANNABINOIDS; DOPAMINERGIC NEURONS; MALE; NEUROGLIA; OXIDATIVE STRESS; PARKINSON DISEASE, SECONDARY; RATS; ROTENONE; SESQUITERPENES;

EID: 84975144673     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-016-2733-y     Document Type: Article

References (43)

1. Gopalakrishna A, Alexander SA (2015) Understanding Parkinson disease: a complex and multifaceted illness. J Neurosci Nurs 47(6):320–326
2. Olanow CW, Tatton WG (1999) Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22:123–144
3. Niranjan R (2014) The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: focus on astrocytes. Mol Neurobiol 49(1):28–38
4. Taylor JM, Main BS, Crack PJ (2013) Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson’s disease. Neurochem Int 62(5):803–819
5. Al Dakheel A, Kalia LV, Lang AE (2014) Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 11(1):6–23
6. Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG (2014) Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: preclinical and clinical outcomes. Biochim Biophys Acta 1842(8):1282–1294
7. Seidl SE, Santiago JA, Bilyk H, Potashkin JA (2014) The emerging role of nutrition in Parkinson’s disease. Front Aging Neurosci 6:36
8. Song JX, Sze SC, Ng TB, Lee CK, Leung GP, Shaw PC, Tong Y, Zhang YB (2012) Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? J Ethnopharmacol 139(3):698–711
9. Mythri RB, Harish G, Bharath MM (2012) Therapeutic potential of natural products in Parkinson’s disease. Recent Pat Endocr Metab Immune Drug Discov 6(3):181–200
10. Hill AJ, Williams CM, Whalley BJ, Stephens GJ (2012) Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther 133(1):79–97
11. Little JP, Villanueva EB, Klegeris A (2011) Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson’s disease. Mini Rev Med Chem 11(7):582–590
12. Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, Xie XQ, Altmann KH, Karsak M, Zimmer A (2008) Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci USA 105(26):9099–9104
13. Chang HJ, Kim HJ, Chun HS (2007) Quantitative structure-activity relationship (QSAR) for neuroprotective activity of terpenoids. Life Sci 80(9):835–841
14. Abbas MA, Taha MO, Zihlif MA, Disi AM (2013) β-Caryophyllene causes regression of endometrial implants in a rat model of endometriosis without affecting fertility. Eur J Pharmacol 702(1–3):12–19
15. Bento AF, Marcon R, Dutra RC, Claudino RF, Cola M, Leite DF, Calixto JB (2011) β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway. Am J Pathol 178(3):1153–1166
16. Cho HI, Hong JM, Choi JW, Choi HS, Hwan Kwak J, Lee DU, Kook Lee S, Lee SM (2015) β-Caryophyllene alleviates d-galactosamine and lipopolysaccharide-induced hepatic injury through suppression of the TLR4 and RAGE signaling pathways. Eur J Pharmacol 764:613–621
17. Zheng X, Sun T, Wang X (2013) Activation of type 2 cannabinoid receptors (CB2R) promotes fatty acid oxidation through the SIRT1/PGC-1α pathway. Biochem Biophys Res Commun 436(3):377–381
18. Choi IY, Ju C, Anthony Jalin AM, da Lee I, Prather PL, Kim WK (2013) Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury. Am J Pathol 182(3):928–939
19. Liu H, Song Z, Liao D, Zhang T, Liu F, Zhuang K, Luo K, Yang L (2015) Neuroprotective effects of trans-caryophyllene against kainic acid induced seizure activity and oxidative stress in mice. Neurochem Res 40(1):118–123
20. Guo K, Mou X, Huang J, Xiong N, Li H (2014) Trans-caryophyllene suppresses hypoxia-induced neuroinflammatory responses by inhibiting NF-κB activation in microglia. J Mol Neurosci 54(1):41–48
21. Cheng Y, Dong Z, Liu S (2014) β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARγ pathway. Pharmacology 94(1–2):1–12
22. Al Mansouri S, Ojha S, Al Maamari E, Al Ameri M, Nurulain SM, Bahi A (2014) The cannabinoid receptor 2 agonist, β-caryophyllene, reduced voluntary alcohol intake and attenuated ethanol-induced place preference and sensitivity in mice. Pharmacol Biochem Behav 124:260–268
23. Assis LC, Straliotto MR, Engel D, Hort MA, Dutra RC, de Bem AF (2014) β-Caryophyllene protects the C6 glioma cells against glutamate-induced excitotoxicity through the Nrf2 pathway. Neuroscience 279:220–231
24. Belanger M, Allaman I, Magistretti PJ (2011) Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 14(6):724–738
25. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT (2009) A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis 34(2):279–290
26. Fujikawa T, Kanada N, Shimada A, Ogata M, Suzuki I, Hayashi I, Nakashima K (2005) Effect of sesamin in Acanthopanax senticosus HARMS on behavioral dysfunction in rotenone-induced Parkinsonian rats. Biol Pharm Bull 28:169–172
27. Sherer TB, Betarbet R, Kim JH, Greenamyre JT (2003) Selective microglial activation in the rat rotenone model of Parkinson’s disease. Neurosci Lett 341:87–90
28. Ojha S, Javed H, Azimullah S, Abul Khair SB, Haque ME (2015) Neuroprotective potential of ferulic acid in the rotenone model of Parkinson’s disease. Drug Des Dev Ther 9:5499–5510
29. Messripour M, Messripour A (2013) Age related interaction of dopamine and serotonin synthesis in striatal synaptosomes. Biocell 37:17–21
30. Pizzimenti S, Ciamporcero E, Daga M, Pettazzoni P, Arcaro A, Cetrangolo G, Minelli R, Dianzani C, Lepore A, Gentile F, Barrera G (2013) Interaction of aldehydes derived from lipid peroxidation and membrane proteins. Front Physiol 4:242
31. Thakur P, Nehru B (2013) Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson’s disease. Neuroscience 231:420–431
32. Sutachan JJ, Casas Z, Albarracin SL, Stab BR, Samudio I, Gonzalez J, Morales L, Barreto GE (2012) Cellular and molecular mechanisms of antioxidants in Parkinson’s disease. Nutr Neurosci 15(3):120–126
33. Albarracin SL, Stab B, Casas Z, Sutachan JJ, Samudio I, Gonzalez J, Gonzalo L, Capani F, Morales L, Barreto GE (2012) Effects of natural antioxidants in neurodegenerative disease. Nutr Neurosci 15(1):1–9
34. Smeyne M, Smeyne RJ (2013) Glutathione metabolism and Parkinson’s disease. Free Radic Biol Med 62:13–25
35. Calleja MA, Vieites JM, Montero-Meléndez T, Torres MI, Faus MJ, Gil A, Suárez A (2013) The antioxidant effect of β-caryophyllene protects rat liver from carbon tetrachloride-induced fibrosis by inhibiting hepatic stellate cell activation. Br J Nutr 109(3):394–401
36. Alvarez-González I, Madrigal-Bujaidar E, Castro-García S (2014) Antigenotoxic capacity of beta-caryophyllene in mouse, and evaluation of its antioxidant and GST induction activities. J Toxicol Sci 39(6):849–859
37. Babu RO, Moorkoth D, Azeez S, Eapen SJ (2012) Virtual screening and in vitro assay of potential drug like inhibitors from spices against glutathione-S-transferase of meloidogyne incognita. Bioinformation 8(7):319–325
38. Doorn KJ, Lucassen PJ, Boddeke HW, Prins M, Berendse HW, Drukarch B, van Dam AM (2012) Emerging roles of microglial activation and non-motor symptoms in Parkinson’s disease. Prog Neurobiol 98(2):222–238
39. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, Laurie C, Gendelman HE (2006) Neuroinflammation, oxidative stress and the pathogenesis of Parkinson’s disease. Clin Neurosci Res 6:261–281
40. Sarkar S, Gough B, Raymick J, Beaudoin MA, Ali SF, Virmani A, Binienda ZK (2015) Histopathological and electrophysiological indices of rotenone-evoked dopaminergic toxicity: neuroprotective effects of acetyl-l-carnitine. Neurosci Lett 606:53–59
41. Swarnkar S, Goswami P, Kamat PK, Patro IK, Singh S, Nath C (2013) Rotenone-induced neurotoxicity in rat brain areas: a study on neuronal and neuronal supportive cells. Neuroscience 230:172–183
42. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson’s disease. Mov Disord 23(4):474–483
43. Littlejohn D, ManFAno E, Clarke M, Bobyn J, Moloney K, Hayley S (2010) Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson’s disease. Parkinsons Dis 2011:713517